Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $35.75.

Several brokerages have recently commented on XNCR. BMO Capital Markets reissued an “outperform” rating and set a $34.00 price objective (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Royal Bank of Canada lifted their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th.

Insider Activity

In other Xencor news, CEO Bassil I. Dahiyat sold 3,366 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the sale, the chief executive officer now directly owns 352,615 shares in the company, valued at $8,469,812.30. This represents a 0.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the transaction, the vice president now owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 121,328 shares of company stock valued at $2,879,673. Corporate insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

A number of institutional investors have recently made changes to their positions in XNCR. Sanctuary Advisors LLC bought a new stake in Xencor during the 3rd quarter valued at $540,000. Geode Capital Management LLC boosted its holdings in shares of Xencor by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock worth $29,273,000 after purchasing an additional 17,658 shares during the period. Barclays PLC grew its stake in shares of Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares during the last quarter. XTX Topco Ltd increased its holdings in Xencor by 113.2% during the 3rd quarter. XTX Topco Ltd now owns 22,080 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 11,725 shares during the period. Finally, Jane Street Group LLC raised its position in Xencor by 18.6% during the 3rd quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company’s stock valued at $3,387,000 after purchasing an additional 26,473 shares during the last quarter.

Xencor Stock Performance

NASDAQ XNCR opened at $25.30 on Wednesday. The company’s 50 day simple moving average is $21.57 and its two-hundred day simple moving average is $20.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor has a 1 year low of $15.31 and a 1 year high of $26.84. The stock has a market capitalization of $1.77 billion, a PE ratio of -7.91 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. The firm’s quarterly revenue was down 81.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.40) earnings per share. Analysts predict that Xencor will post -3.71 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.